Nonstandard exception requests (NSERs), for which transplant centers provide patient-specific narratives to support a higher Model for End-stage Liver Disease/Pediatric End-stage Liver Disease score, are made for >30% of pediatric liver transplant candidates. We describe the justifications used in pediatric NSER narratives 2009-2014 and identify justifications associated with NSER denial, waitlist mortality, and transplant. Using United Network for Organ Sharing data, 1272 NSER narratives from 1138 children with NSERs were coded for analysis. The most common NSER justifications were failure-to-thrive (48%) and risk of death (40%); both associated with approval. Varices, involvement of another organ, impaired quality of life, and encephalopathy were justifications used more often in denied NSERs. Of the 25 most prevalent justifications, 60% were not associated with approval or denial. Waitlist mortality risk was increased when fluid overload or "posttransplant complication outside standard criteria" were cited and decreased when liver-related infection was noted. Transplant probability was increased when the narrative mentioned liver-related infections, and fluid overload for children <2 years old; it decreased when "posttransplant complications outside standard criteria" and primary sclerosing cholangitis were cited. This analysis provides novel insight and suggests targets for future consideration in outcomes research and exception criteria. Changes in the allocation system are needed to ensure equity and optimize outcomes for all pediatric candidates.
Introduction
The Model for End-stage Liver Disease (MELD) and Pediatric End-stage Liver Disease (PELD) scoring systems were implemented in 2002 to prioritize liver transplant candidates based on "objective and measurable medical criteria." The system was designed to minimize waitlist mortality (1) . But even data from 2 years after MELD/ PELD implementation suggested that the scores might not adequately describe transplant urgency for pediatric liver transplant candidates (2) . Since then, more than half of listed children have been granted "exceptions" to increase their MELD/PELD score and expedite transplantation (2, 3) .
In addition to standardized exceptions, such as for hepatocellular carcinoma or urea cycle disorders, nonstandard exception requests (NSERs) have been highly used-in >40% of pediatric liver transplant candidates from 2009 to 2014 who are listed by calculated MELD/PELD. More than 90% of NSERs are approved. Compared with children with no exception requested, those with an approved NSER have higher odds of transplantation and reduced risk of posttransplantation death after adjustment for other factors (3, 4) . Despite the low prevalence of NSER denial, those who are denied have a lower likelihood of transplantation, increased risk of waitlist mortality, and, for those who are eventually transplanted, increased risk of posttransplantation death compared with those with no NSER or with approved NSERs (3, 4) .
Each NSER is based on a narrative and request for a specific MELD/PELD score, submitted by the transplant center to the regional review board (RRB). Per United Network for Organ Sharing (UNOS) policy, NSER applications must "justify why accepted medical criteria support that the candidate has a higher MELD/PELD score" and "explain how the patient's current condition and potential for benefit would be comparable to that of other [s] " with that score (5) . The narrative summarizes the patient and his or her illness, complications, and justifications for NSER. But there is no formal guidance on what constitutes "accepted medical criteria" or when to submit an NSER for pediatric candidates.
RRB composition and specific procedures vary by region. In some regions, all transplant centers are represented on the RRB (e.g. Region 6); in others (e.g. Region 5), voting membership rotates-with seven serving at any given time. RRB members-which include transplant physicians and surgeons from centers in the region-are alerted to an NSER via email and have 21 days to vote on the case. A brief comment may be submitted by RRB members who deny an NSER; these are provided to the submitting center. Transplant centers can appeal a denial, either in written form or by requesting a conference call discussion with the RRB. But the narratives have not otherwise been available for review and are not included in the standard-release Scientific Registry of Transplant Recipients (SRTR) database. This is the first analysis of UNOS NSER narratives that focus on pediatric liver transplant waitlist candidates. Our aims were (1) to describe the justifications used in NSER narratives and (2) to investigate which justifications are associated with NSER denial, waitlist mortality, and transplantation. We used content analysis, in which qualitative data are coded and analyzed quantitatively, to code the narrative justifications (6, 7) .
Methods

Cohort selection
We used the SRTR, which includes data on all waitlisted candidates in the United States, as submitted by Organ Procurement and Transplant Network (OPTN) member centers. The Health Resources and Services Administration (HRSA), US Department of Health and Human Services, provides oversight to the activities of the OPTN and SRTR contractors. Institutional review board approval from the University of California, San Francisco, was obtained before analysis (CHR 14-15024).
Included were pediatric liver transplant waitlist candidates, aged 0-18 years at listing, who were listed between 1 January 2009 and 31 December 2014. To focus on the impact of NSER justifications within the group that had NSERs, we excluded waitlist candidates with no exception requests and those who were initially listed as status 1a or 1b, inactive, or with a "standard" exception that earned automatic MELD/PELD exception points. "Standard" exceptions included hepatocellular carcinoma (HCC) within criteria, metabolic liver disease, hepatoblastoma, primary hyperoxaluria, hepatopulmonary syndrome or portopulonary hypertension, familial amyloidosis. We classified liver transplant indication based on the categories defined by the Studies in Pediatric Liver Transplant (SPLIT) Research Group (8) . Center volume was calculated as mean pediatric liver transplants per year, using annual data from 2009 through 2014 (9) .
Narrative analysis
The narratives submitted with each NSER were obtained from OPTN, after HRSA approval. For each waitlist candidate, we analyzed narratives accompanying the first approved NSER and all denials before the first approval, or all denials for those with no approvals. All narratives were read and coded by two authors (H.B., E.P.) using a content analysis approach (6, 7) . Before beginning review of the narratives, the author group generated an a priori list of likely NSER justifications based on our experience running a pediatric transplant program and our review of literature on factors associated with transplantation and waitlist mortality in pediatric liver transplant candidates. We added to the list of justifications during narrative review as needed to cover all themes. Each justification was coded as present or absent for each narrative. Narratives for which one reviewer was uncertain was reviewed by the other reviewer, and a random sample of narratives were cross-reviewed to ensure consistency in coding. Justifications were grouped to allow for summary by main themes, as demonstrated in Table S1 .
Statistical analysis
Continuous variables were reported as mean AE SD, with p-value by ANOVA, if normally distributed with equal variances. For skewed distribution and/or unequal variances (Bartlett's test p < 0.05), median (interquartile range), with Kruskal-Wallis testing, was reported. Categorical variables, including NSER justifications, were compared with the use of v 2 testing.
Only data from a patient's first listing within the study period were used for outcomes analysis. For the NSER justifications and NSER-specific data, data from the first NSER within that listing were used.
Factors associated with NSER denial were evaluated by using logistic regression. Competing risks regression was used to evaluate association of predictors with (1) liver transplantation and (2) waitlist mortality, defined as a death or waitlist removal for being too sick to undergo transplantation (10) . NSER justifications mentioned in ≥5% of all NSERs were considered in univariate analysis, as were patient characteristics. Variables with p < 0.20 were tested in multivariable models, and factors were eliminated by using backward stepwise selection. Because we identified an interaction between age and waitlist mortality in previous analysis, we evaluated each variable for interaction with age; interactions with p < 0.05 were retained. Observation time was measured from the date of listing for transplantation to waitlist death, liver transplantation, or last date on the waitlist for patients still waiting or removed for other reasons.
To assess whether NSER justifications had an impact on approval after an initial denial, McNemar's v 2 test for paired data was u2ed. SAS version 9.4 (SAS Institute, Cary, NC) or Stata/IC 14 (StataCorp, College Station, TX) was used for analyses.
Results
After initial exclusions, our cohort included 1215 children who had NSERs. After additional exclusions, 1272 NSER narratives on 1138 pediatric liver transplant candidates were coded (Figure 1 ). Of those children with NSERs, 82% had only approved NSERs, and 5% had an initial approval with later denial-these participants were combined in the NSER approval group. Nine percent had initial NSER denial with eventual approval, and only 4% of children had denials without approvals.
Subjects with initial NSER denial were older, less likely to have biliary atresia, and less likely to have public insurance. Although those with initial NSER denial had higher listing MELD/PELD and 70% eventually had an NSER approved, they spent significantly longer on the waitlist and had significantly lower allocated MELD/PELD at transplantation than did those with initial NSER approval. For those transplanted, donor type did not differ by NSER status (Table 1) .
NSER narrative justifications and association with NSER approval or denial We examined the prevalence of each coded justification in the first NSER narrative and their association with initial NSER approval or denial. Justifications mentioned in >5% of coded NSER narratives are included in Table 2 , and a full list is provided in Table S1 . Specific complications of liver disease were cited in 86% of narratives, but overall the mention of any complication was not associated with NSER approval or denial. The most common complication was failure to thrive (FTT, 48% of all NSERs), and NSERs noting FTT were more likely to be approved. Explicit mention of "risk of death" was the second most common and also was associated with approval. However, most justifications were associated with neither approval nor denial (Tables 2 and S1 ).
Use of some justifications was associated with increased odds of NSER denial. Mention of a diagnosis or complication that qualified for standard MELD/PELD exception points but for which the patient was outside of established criteria occurred in 34% of all NSER narratives but was more commonly cited in denied than in approved NSER narratives. Varices, involvement of another organ system, impaired quality of life, and encephalopathy were also mentioned significantly more often in denied NSERs (Tables 2 and S2 ).
In multivariable analysis, NSER denial was associated with both impaired quality of life and involvement of the renal system. None of the NSER justifications remained significantly associated with NSER approval. Also associated with NSER denial were older age, higher MELD/ PELD score at listing, and being listed in Region 5 ( Table 3) .
Association of NSER justifications with waitlist mortality and transplantation Waitlist mortality risk was increased when fluid overload or posttransplantation complications outside of standard exception criteria were included as NSER justifications (p < 0.05, Table S3 ). Both factors retained significance in multivariable analysis (Table 3) . Decreased risk of waitlist mortality was identified for patients with narratives noting liver-related infection or cholangitis (Tables S3 and 3) . Probability of transplantation was increased in univariate analysis for NSER justifications of risk of death, fluid overload, and liver-related infection-specifically cholangitis. In multivariable analysis, increased probability of transplantation remained associated with liver-related infection and fluid overload, the latter only in children See Results and Tables 3 and S2 for statistical significance in analysis of waitlist mortality. Includes all justifications with ≥5% prevalence in initial NSER narratives. See Table S1 for full listing, subcategories, and prevalence of all justifications coded from the NSER narratives.
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"Involvement" of other organ system includes organ disease or dysfunction caused by liver disease or as underlying/associated condition.
<2 years old at listing. Probability of transplantation was decreased for patients with NSER narratives describing fat-soluble vitamin deficiencies, varices, impaired quality of life, encephalopathy, posttransplantation complication outside of standard criteria, and autoimmune hepatitis (AIH)/primary sclerosing cholangitis (PSC). In multivariable analysis, probability of transplantation remained significantly reduced for patients with NSERs indicating varices, posttransplantation complication outside standard criteria, and PSC/AIH in older children (Tables S3  and 3 ).
The variable most strongly associated with increased risk of waitlist mortality and decreased likelihood of transplantation was previous liver transplantation, with complications that did not fit criteria for automatic exceptions. Of these 98 children, 20 (20%) had hepatic artery thrombosis outside of the 14-day window; none died on the waitlist. Eleven children (11%) died or were removed from the waitlist; four had chronic rejection, four had vascular insufficiency, two had infected biliary strictures, and one had AIH. Nine were 7-18 years old at relisting; three had denied NSERs and eight had approved NSERs. Of the 67 children retransplanted, seven patients died within 1 month posttransplantation, after spending 23-895 days on the waitlist. Cause of death was graft dysfunction in three, hemorrhage in two, and multiorgan failure/sepsis in two. Three died >6 months posttransplantation. Table S3 for full listing of odds ratios (ORs), hazard ratios, and statistical significance in univariate analysis. 2 Statistical interaction by age category, as noted in table. In the transplant model, interaction variable statistical significance: p = 0.01 for interaction between fluid overload and age, p = 0.04 for interaction between PSC/autoimmune hepatitis and age. 3 No waitlist deaths or removals for being too sick for transplantation in the PSC/autoimmune hepatitis group.
Of 110 children whose narratives noted tumor outside standard criteria, 88 were transplanted. Seven died posttransplantation (8%), all 6 months to 2 years posttransplantation of disease recurrence; all had NSERs approved pretransplantation. The 92% of these children who were alive posttransplantation had a median follow-up of 673 days (IQR 285-1437 days).
Regional variation in requested MELD/PELD scores At first NSER, median calculated MELD/PELD was similar across regions, ranging from 8 in Region 4 (IQR 1-14) to 14.5 in Region 1 (IQR 8-20.5) (Figure 2 ) There were no statistically significant differences in calculated MELD/ PELD at NSER or requested MELD/PELD between those with initial approval and those with initial denial in any region (p > 0.05) (Figure 2 , A vs. D for each region).
Changes in the NSER between denial and approval: MELD/PELD requests and narrative justifications
We next compared the approved and denied NSERs in patients who had both. Eighty-one patients had one NSER denial preceding an approval. Compared with those patients with only approvals (n = 997), patients with one denial followed by approval were older (median at listing 13 years [IQR [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] vs. 1 year [IQR 0-9] for only approvals, p < 0.001) and less likely to have biliary atresia (19.7%, vs. 49.7%, p < 0.001). Subjects with one denial before approval were more likely to be listed in Region 5 (38%, vs. 9.4% of only approvals) or Region 10 (12.4%, vs. 6.7%, p < 0.001 for all regions). There were no significant differences by calculated MELD/PELD at listing (median 9 for both, p = 0.95) or at waitlist removal (median 11 for denial/approval, 12 for only approvals, p = 0.74), gender, race/ethnicity, or insurance type (data not shown). Outcomes were comparable, with 77.8% of the denial/approvals and 82.1% of the only approvals undergoing transplantation and 3.7% and 5.0% dying while on the waitlist or being removed for being too sick, respectively.
In these 81 patients, median requested score for the initial denial was 30 (IQR 24-30), and for the subsequent approval, the score was 25 (IQR 22-30, p < 0.001). Median decrease in requested points was 3 (IQR 0-7). Whether a justification was mentioned in the NSER did not change for most subjects between denial and approval (range 79.0-97.6% of narratives for each justification had no change; Table S4 ). The only justifications for which addition was associated with approval were sepsis (added to 4.9% of narratives, p = 0.01), involvement of any organ system (added to 16%, p = 0.03), and developmental delay worsened by liver disease (added to 7.4%, p = 0.01). The most commonly added between denial and approval were complications of liver disease (added to 13.6% of narratives), FTT (9.9%), impact on quality of life (9.9%), and involvement of any organ system (16.0%), particularly of the renal system (7.4%).
NSER changes for those with multiple denials Fourteen patients had two denials followed by approval. One patient with posttransplantation lymphoproliferative disorder (PTLD), cholangitis, and chronic rejection became too sick to undergo transplantation. Of the seven patients who underwent transplantation, four had narratives that described worsening complications of liver disease: ascites, FTT, variceal bleeding, and cholangitis. The fifth had HCC outside criteria, and two had no substantive changes to the narrative. Two who reached transplantation had no changes in requested MELD/PELD between denial and approval (30 points requested), three had increased requests of 3-4 points, and two had decreases (23 to 21 and 28 to 22). All six who improved or were still waiting had decreases in their requested scores between denial and approval of 2-10 MELD/PELD points.
Four patients had three or four denials preceding an approval. Three patients were teenagers, 12-18 years old. One with biliary atresia and HCC had four NSER denials before an approval; there were no changes in narrative during this process. A second who underwent initial liver transplantation for acute liver failure and developed biliary strictures with recurrent cholangitis as well as a PTLD-like process requiring bone marrow transplantation had three denials followed by an approval. MELD request was decreased from 40 to 22; the patient remained listed at data censoring. A third adolescent underwent initial liver transplantation for PSC, complicated by strictures and chronic infections. MELD request decreased from 40 to 22, and transplantation occurred after >1 year on the waitlist. The fourth patient was a child with AIH and PSC who was approved after developing FTT despite supplementary feeding and biliary abscesses. This patient was recorded as a transfer to another center.
NSERs in patients with no approvals
There were 42 patients with only denials: 32 patients had one denial, nine had two denials, and one had four denials. Of those 42 patients, 16.7% died or became too sick for transplantation-compared with 5.0% of those with only approvals. Seventy-one percent of those with only denials were transplanted-compared with 82.2% of those with only approvals (p = 0.005). Patients with only denials had higher median calculated MELD/PELD at listing (15.5, IQR 8-21, p < 0.001) and at waitlist removal (19, IQR 10-26, p < 0.001) but lower allocated MELD/ PELD at transplantation because of exception points (median 21, IQR 10-27, p < 0.001) than those with only approvals (listing: 9, 2-16; waitlist removal: 11, 4-21; allocation 30, IQR 25-38). Twenty-six percent of those with only denials were in region 5, compared with 9.4% of those with only approvals (n = 997, p = 0.03).
The 32 patients with only denials were significantly older than those with only approvals (median 13.5 years, IQR 0.5-17 vs. median 1, IQR 0-9, p < 0.001) but there was no difference in distribution of diagnoses (p = 0.81, prevalence not shown). In their NSER narratives, children with only one denial were more likely to have hyponatremia (12.5% vs. 3%, p = 0.01). encephalopathy (19% vs. 8.5%, p = 0.05), sepsis (19% vs. 8%, p = 0.05), impaired quality of life (22% vs. 8%, p = 0.007), and involvement of another organ system (37.5% vs. 18%, p = 0.005) than did those with only approvals.
Among the nine patients with two denials and no approvals, all were 10-18 years of age at listing. Two died or were removed because they were too sick (22%). One recovered, and six underwent transplantation. Of the five who received deceased donor transplants, four had NSER narratives noting fluid overload; three of those also noted bleeding varices and risk of death.
Discussion
This is the first analysis of NSER narratives to focus on pediatric liver transplant candidates since implementation of the MELD/PELD scoring system in 2002. It is intended to describe what justifications are commonly used for pediatric NSERs, not to prescribe what they should contain or which should be approved.
Although each narrative is personalized, we identified similar themes across most narratives. Many justifications commonly used in these NSER narratives are not factored into the MELD/PELD but are linked to lifethreatening events. One other review of adult and pediatric NSERs, using UNOS 2005-2008 data, also identified ascites, infections, "wasting," and varices as the most common justifications for pediatric NSERs (11) . In our analysis, NSER approval was associated with only three of the 25 most common justifications in univariate analysis. In multivariable analysis, the likelihood of NSER approval was associated with age at listing and regionbut none of the NSER justifications. This suggests that NSER approval may be primarily based on factors outside of the narrative.
Patients with NSER denials followed by approvals had few changes in their NSER narratives. Most adjustment was in the requested score. This could reflect RRB opinion on the patient's mortality risk-or opinion on other factors, like where the exception score would place patients relative to others on the waitlist. System efficiency might be increased by including a standardized list of justifications in NSER submissions-either to guide the narrative or as a checklist to replace it. Because most appeals involved a change in score request with little to no change in the narrative, we could also allow for adjustment of the requested score within the application or through RRB recommendation.
Several NSER justifications were more likely to be mentioned in denied than in approved NSERs. Some of these justifications may not be compelling to RRBs. For example, the association of standard exception categories outside criteria with denial may reflect attempts to maintain system integrity. Others might be used when more convincing reasons are not applicable. For example, "impaired quality of life" and "encephalopathy" may be associated with denial because they were often described in patients who lacked directly life-threatening complications like bleeding varices or infections.
Comparing predictors of NSER approval/denial with those of waitlist mortality and transplantation provides insight into what groups the current system may adequately advocating for-and which are left vulnerable. Risk of death, FTT, and biliary complications were associated with NSER approval but not transplantation or waitlist mortality. This may indicate that the NSER system appropriately factors these issues into waitlist priority. However, posttransplantation complications outside standard exception criteria were associated with decreased probability of transplantation and increased risk of death. These children appear to be at higher risk than currently accounted for in the system. We found substantial regional variability in NSER approval rates, as has been reported previously (3, 11, 12) . Region remained a significant predictor of NSER approval and transplantation, but not waitlist mortality, in this cohort. In previous analyses that included children without exception requests, region was not a significant predictor of transplantation, waitlist mortality, or posttransplantation death; NSER approval and denial did affect all three outcomes in that larger population (3, 4) . Listing at a low-volume center (fewer than five pediatric liver transplantations annually) has also been associated with lower transplantation probability and higher mortality risk (13) . Children listed at high-volume centers were more likely to be transplanted. Center volume was not associated with other outcomes. However, we did not examine whether children at low-volume centers were less likely to have NSERs filed.
Within each region, neither laboratory MELD/PELD scores at NSER nor requested MELD/PELD scores were significantly different between the approved NSER versus the denied NSER. Requested scores were generally higher in regions with higher median allocation MELD for adult liver transplant recipients-suggesting that transplant centers are calibrating their requests to "competition" for organs in the region. Potential behavioral changes in response to policy changes should be considered in planning system changes.
The high prevalence, and limited set, of common justifications supports that idea that more uniform and transparent NSER policies and practices could be generated by the pediatric liver transplant community. OPTN is planning to replace RRBs with national review boards, with a separate committee for pediatric candidates (https://optn.trans plant.hrsa.gov/governance/public-comment/national-liverreview-board/). The pediatric national review board will include one member from each pediatric transplant center, and each NSER decision will be made by five randomly selected members of that board. Our analysis provides some insight for review board members and transplant centers into common components of NSER narratives nationally.
A national review board system offers an important opportunity to equalize NSER practices across regions but does not ensure transparency of the system or optimization of priority ranking. It should help ensure that decision-makers about pediatric NSERs have expertise about pediatric liver disease and mortality risk factors. Periodic published summaries of review board decisions would give transplant centers some additional insight into how the system operates.
Ongoing work to build the evidence basis on which NSER decisions are made and to standardize decisions is also crucial. The justifications associated with waitlist mortality and transplantation could be targets for future research and for consideration in standardized exception criteria. For example, fluid overload was associated with increased transplant probability in younger but not older children and with increased risk of waitlist mortality. Ascites has previously been associated with waitlist mortality in pediatric patients (14) , but recent UNOS guidance recommended against NSERs for ascites in adult candidates (15) .
Hyponatremia has been linked to waitlist mortality in pediatric patients (14, 16) and was recently added to MELD scores but was rarely mentioned in the pediatric NSERs. For adults, serum sodium and creatinine may capture mortality risk associated with ascites. But this may not be accurate for adolescents-for whom creatinine is lower than in adults-and children-as neither sodium nor creatinine is in the PELD. Future research into how FTT could be more accurately classified may also help with risk stratification. For example, a growth chart provided with NSERs could provide an objective, standardized picture of FTT severity and trajectory. Or an accompanying photograph could allow for an "eyeball test," more formally termed "subjective global assessment," of illness severity (17).
Two recent documents from UNOS provide evidencebased guidance on common justifications for adult NSERs. Similar guidance for pediatric NSERs-which will require additional research to provide an robust evidence basis-could help standardize approvals for review board members (15, 18) .
In this analysis, we reviewed the entire population of pediatric NSER narratives. This should minimize sampling bias. We used the narratives to deduce what transplant centers thought was important or effective, but we cannot discern how they decided which justifications to include. It is possible that we missed themes or coded justifications differently than other investigators might have done. Data on transplantation offer acceptance/refusal were not available for this analysis; connecting that data to the NSER data would allow for additionalalthough still indirect-insight into transplant centers' decision-making. Not captured in the UNOS database is direct information about what details influence reviewer decision-making. We also acknowledge that each individual's story is complex and multifaceted-we have not yet identified clusters of justifications that affect NSER approval or denial or could act as a harbinger of dangerous outcomes.
In summary, this analysis suggests that the current NSER narrative system may not be efficient or effective for prioritizing pediatric liver transplant candidates by "objective and measurable" medical criteria, particularly given the differential impact that NSERs appear to have on transplantation and survival for older children and by region for all children, UNOS should appoint a working group to focus on improvements to the MELD/PELD system as it applies to pediatric candidates. The NSER narratives do provide insight into how pediatric transplant centers justify NSERs and which justifications may or may not compel RRBs. To optimize equality and outcomes for pediatric liver transplant candidates, further work is required to build the evidence basis on which NSER decisions are made and to adjust policy so that we can decrease the need for NSERs. 
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S3 : Univariate associations between demographics, NSER justifications, patient location, and outcomes.* Table S4 : Changes in the justifications included in NSER narratives of 81 children who had one NSER denial followed by NSER approval.
2154
American Journal of Transplantation 2017; 17: 2144-2154
